SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as the community anticipates upcoming clinical data for its lung cancer program and maintains bullish sentiment regarding the company's platform, commercial momentum, and path to profitability. While some participants expressed impatience for specific financial guidance, the overall discussion remains focused on the potential for institutional accumulation and the long-term value of the company's oncology pipeline.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The primary catalyst for XRP is the failure of the U.S. Senate to pass the Crypto Clarity Act, leading to widespread disappointment, market volatility, and intense political finger-pointing among community members. While many traders expressed frustration over the legislative stall, a significant portion of the community remains focused on long-term adoption or view the price decline as a buying opportunity.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending following significant open market insider purchases by the CEO and a director, which the community interprets as a strong bullish signal. Traders remain divided on the long-term outlook, with some viewing the insider buys as a sign of a bottom, while others express skepticism regarding management's performance and core brand stability.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is facing persistent downward pressure as investors weigh macroeconomic headwinds, including high interest rates, rising oil prices, and overall weakness in the housing sector. While some traders express frustration over consistent declines and share dilution, others maintain a long-term bullish thesis, citing CEO Brad Jacobs' track record and the company's aggressive M&A strategy as reasons to accumulate shares at current levels.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

The conversation is dominated by frustration regarding the stock's recent downward price trend and volatility, with participants debating whether current levels present an accumulation opportunity or indicate further decline. Traders are specifically focused on the impact of the LivePerson acquisition, speculation about potential short squeezes, and reactions to the appointment of a new CFO.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending significantly lower as investors react to the expiration of its post-IPO insider lock-up period, which has increased the potential selling supply. While some traders view the decline as an opportunity to initiate or add to positions given the company's drone-related growth prospects, others remain cautious about the firm's path to profitability and potential for further dilution.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following positive top-line Phase 3 results for plozasiran in treating severe hypertriglyceridemia, with the community highlighting deep, durable triglyceride reductions and a significant decrease in acute pancreatitis events. While many traders are bullish on the company's RNAi platform and potential commercial outlook, others express frustration over intraday price volatility and what they perceive as institutional market manipulation.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Investors are focused on the potential for Fannie Mae and Freddie Mac to exit government conservatorship, driven by anticipation of an IPO or uplisting initiative supported by the current administration. While many traders remain bullish on the long-term potential of the mortgage giants, discussions frequently highlight frustration with the ongoing lack of a specific timeline and the persistent speculative nature of the OTC-traded assets.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending following a rally driven by investor optimism over its pipeline development, including potential progress in ERCOT's Batch Zero process for its Texas projects and the company's initiative to develop on-site natural gas infrastructure for its data centers. Traders remain divided, however, as some anticipate further upside as regulatory uncertainty clears, while others express concern over the lack of specific disclosures regarding project classifications and broader macroeconomic pressures on the sector.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as traders speculate on potential price manipulation and express frustration over the stock failing to react to high oil prices, massive contract backlogs, and ongoing geopolitical tensions in the Middle East. Discussion remains heavily focused on the impact of high short interest and the upcoming merger with Valaris as key factors influencing the stock's price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing...

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...

Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...

Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE

Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Equity

Bearish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.14	--	--	N/A
Q2 '26	-$1.14	-$1.11	2.76%	BEAT
Q1 '26	-$1.18	-$1.17	0.81%	BEAT
Q4 '25	-$1.19	-$1.31	-10.52%	MISSED
Q3 '25	-$1.15	-$1.15	0.21%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

XENE Earnings

Upcoming Earnings: Q3 '26

Historical Earnings